• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)

by Jasmine Pennic 08/14/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

FDA Cancer COE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.

Methods to Derive RWE From Multiple Sources including EHRs

As part of this research collaboration, Syapse and the FDA will investigate methods to derive RWE from multiple sources including, and going beyond, electronic health records (EHRs). The “Framework for FDA’s Real-World Evidence Program” describes the challenges in obtaining comprehensive data from EHRs and claims, and the difficulty in linking sources. This collaboration will utilize real-world data integrated from many source systems, including clinical data from EHRs and registries, and molecular data from testing labs, and seek to characterize the regulatory suitability of RWE derived from this multi-source approach.

RWE Use to Support Precision Medicine & Oncology

Additionally, Syapse and the FDA will examine real-world endpoints for solid tumors and hematological malignancies, characterizing the usage and clinical impact of molecular testing, understanding outcomes and adverse events in patients receiving precision medicines relative to clinical trial populations, and incorporating patient-reported outcomes into RWE.

Alongside these direct collaboration efforts, Syapse will engage oncologists in its Learning Health Network in joint outcomes research. This work will support Syapse in enabling the use of RWE by oncology care providers to inform care decisions and outcomes research. In turn, Syapse will incorporate the outcomes derivation methodology into its Learning Health Network capabilities.

Why It Matters

“Advances in real-world evidence present an opportunity to learn from patients and potentially translate those insights into safer and more effective therapies,” said Sean Khozin, MD, MPH, associate director for oncology regulatory science and informatics in the FDA’s Oncology Center of Excellence. “Real-world evidence from well-designed studies meeting appropriate data quality standards can help to inform decision-making and provide information regarding the impact of new therapies in real-world patient populations, particularly those not represented in clinical trials. This is especially critical in precision medicine, where understanding all of the factors that may drive safety and response is both imperative and difficult to capture at scale using traditional clinical trials.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: cancer, Clinical Trial, Clinical Trials, FDA, MD, Oncology, Precision Medicine, Precision Oncology, Real World Evidence (RWE), Syapse

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |